Johnson Financial Group Inc. Boosts Stock Position in IDEXX Laboratories, Inc. $IDXX

Posted by Stanley Muller on Jul 22nd, 2026

Johnson Financial Group Inc. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 2,994.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,671 shares of the company’s stock after acquiring an additional 1,617 shares during the period. Johnson Financial Group Inc.’s holdings in IDEXX Laboratories were worth $939,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of IDXX. Elyxium Wealth LLC purchased a new stake in IDEXX Laboratories during the fourth quarter worth about $3,666,459,000. State Street Corp boosted its stake in shares of IDEXX Laboratories by 4.0% in the fourth quarter. State Street Corp now owns 3,656,626 shares of the company’s stock valued at $2,473,817,000 after purchasing an additional 138,956 shares during the period. J. Stern & Co. LLP grew its holdings in shares of IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after purchasing an additional 2,642,200 shares in the last quarter. Geode Capital Management LLC increased its stake in IDEXX Laboratories by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock worth $1,749,380,000 after buying an additional 86,263 shares during the period. Finally, Invesco Ltd. increased its stake in IDEXX Laboratories by 13.8% during the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock worth $1,016,296,000 after buying an additional 181,955 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 2.0%

Shares of NASDAQ:IDXX opened at $552.46 on Wednesday. The firm’s 50 day moving average price is $555.50 and its 200 day moving average price is $597.62. The stock has a market cap of $43.58 billion, a price-to-earnings ratio of 40.68, a price-to-earnings-growth ratio of 3.08 and a beta of 1.55. IDEXX Laboratories, Inc. has a fifty-two week low of $518.55 and a fifty-two week high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the firm earned $2.91 earnings per share. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research reports. Citigroup assumed coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price on the stock. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Finally, UBS Group decreased their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

Read Our Latest Stock Analysis on IDEXX Laboratories

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.